Company news from the 02/13/07 news brief

Share this article:
CBI Research has partnered with Medical Broadcasting Company (MBC) to conduct a survey on how pharmaceutical marketers are utilizing digital media. Marketers can participate by visiting www.mbcnet.com. Those who take part in the survey can enter their e-mail address for a copy of the report and an opportunity to win an iPod Shuffle. Survey results will be unveiled by Bruce Grant, MBC SVP, at CBI’s 6th Annual eMarketing for the Pharmaceutical Industry Conference, on March 7-9, in Philadelphia. Watson Pharmaceuticals, has reached a settlement with GlaxoSmithKline on outstanding patent litigation related to Wellbutrin XL (bupropion hydrochloride) extended-release tablets 150mg. In December 2005, Andrx Corporation filed a patent infringement lawsuit in the U.S. District Court for the Southern District of Florida against GlaxoSmithKline alleging that Glaxo's Wellbutrin XL150mg product infringed Andrx's US patent. Watson acquired Andrx in November 2006. Under terms of the settlement, Andrx will receive a one-time payment of $35 million, and has granted GlaxoSmithKline a royalty-bearing license to the Wellbutrin patent. Other terms of the settlement and license are confidential, Watson said. Corbett Accel Healthcare Group unveiled its new Web site during the company’s annual state of the company celebration event, held simultaneously in Chicago and New York through a satellite feed. The Web site can be found at www.corbettaccel.com. “This site reflects our distinct differences from other healthcare communications networks,” said Scott Cotherman, CEO of Corbett Accel. “The Web site also now demonstrates what the industry has been saying about Corbett Accel for years — we are a company that delivers on building bigger brands faster through the development of a supra-culture that attracts and nurtures top talent who are dedicated to producing MarketMovingIdeas.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...